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ABSTRACT
Background: Hydroxyethyl starch (HES) is a type of colloid fluid that is commonly used for volume resuscitation of pa-
tients admitted to the intensive care unit. Data regarding the renal consequences of HES are conflicting.
Purpose: To evaluate the effect of HES solutions on renal outcomes and mortality among critically ill patients requiring 
acute volume resuscitation.
Data sources: We searched electronic databases (MEDLINE, EMBASE, the Cochrane Central Registry of Controlled Tri-
als and the SCOPUS database) from 1950 to 2008. Conference proceedings and grey literature sources were searched from 
2002 to 2007.
Study selection: We included only randomized controlled trials of acute volume resuscitation of critically ill patients com-
paring HES fluid with an alternative resuscitation fluid. 
Data synthesis: Two reviewers independently assessed trial eligibility, extracted data and evaluated trial quality. Random-
effects models were used for all summary measures of effect. 
Results: Twenty-two trials (n = 1865 patients) were included. Patients who received HES were more likely to have received 
renal replacement therapy (odds ratio [OR] 1.90, 95% confidence interval [CI] 1.22–2.96, I2 9.5%, n = 749). There was no 
difference in overall mortality (OR 1.07, 95% CI 0.85–1.34, n = 1657). However, in trials that included patients with severe 
sepsis and septic shock, in high-quality and multicentre trials, and in trials with adequate allocation concealment, there 
was a trend toward increased risk of death in association with HES.  
Limitations: Data regarding adverse events, including renal outcomes, were not reported in the majority of published ran-
domized trials. Considerable clinical and methodologic heterogeneity existed among trials. 
Conclusions: The use of HES for acute volume resuscitation of critically ill patients, and in particular those with severe 
sepsis and septic shock, appeared to be associated with increased use of renal replacement therapy. Further randomized 
controlled trials evaluating clinically important end points are required to examine the efficacy and safety of HES fluids for 
critically ill patients.
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ntravenous  fluid  resuscitation  is  essential 
for preventing organ failure and death1 in critically 
ill patients. Intravenous fluids are broadly categor-
ized as crystalloids (solutions that can pass through a 
semipermeable membrane) or colloids (suspensions in 
which fine particles of one substance are spread evenly 
throughout another).  
Crystalloid  solutions  are  inexpensive  and  read-
ily  available,  and  they  do  not  cause  allergic  reactions 
or infection. Colloid resuscitation requires less volume 
and less time and may sustain intravascular volume for 
longer durations than crystalloid resuscitation.2 Despite 
considerable research over several decades, debate per-
sists regarding which of these types of solution offers the 
greatest relative advantage.3
Hydroxyethyl starch (HES) is one example of a col-
loid solution that is widely used for fluid resuscitation. 
However,  acute  kidney  injury  has  been  intermittently 
reported with the use of HES in various patient popu-
lations.4–7  Although  the  pathophysiologic  mechanism 
is  unclear,  it  is  possible  that  microscopic  changes  re-
ferred to as “osmotic nephrosis-like lesions” (histologic 
lesions that are thought to be related to changes in os-
motic pressure)4,8 may cause the kidney damage. Acute 
kidney injury is an important adverse outcome in critic-
ally ill patients because it is an independent risk factor 
for mortality, increasing the risk of long-term morbidity, 
impaired quality of life and possible dependence on di-
alysis.9–12 Some critically ill patients, such as those with 
severe  sepsis  or  septic  shock,  are  at  increased  risk  of 
acute kidney injury because of underlying chronic kid-
ney disease and other comorbidities, older age and/or the 
septic process itself. This population may be especially 
vulnerable to the effects of resuscitation fluids known 
to adversely affect kidney function. The evidence about 
adverse renal outcomes associated with administration 
of HES from observational studies13–16 and randomized 
controlled trials7,17–19 is conflicting. 
Previously  published  systematic  reviews  of  colloids 
for resuscitation have focused on patients with sepsis 
or have not reported renal outcomes.2,20–22 The object-
ive of the current study was to perform a quantitative 
systematic review of randomized controlled trials com-
paring HES with some other intravenous fluid for acute 
fluid resuscitation of critically ill patients. Our primary 
outcome of interest was rate of acute kidney injury. Our 
secondary outcomes were mortality, duration of mech-
anical ventilation, duration of stay in the intensive care 
unit (ICU), allergic reactions, bleeding and transfusion 
of packed red cell units. 
Methods
Study sources and searches. Before commencing this 
systematic review, we planned all aspects of the study 
protocol, including the clinical question, search strategy, 
outcomes and analysis. 
We first developed a strategy to search Ovid MED-
LINE (1950 to 2007 August week 2). This search strategy 
was adapted to search EMBASE (1980 to 2007 week 33) 
and the Cochrane Central Register of Controlled Trials 
(to third quarter 2007). The search strategy was refined 
by an information specialist at The Ottawa Hospital, who 
incorporated highly sensitive terms to identify clinical 
studies.23 The search was updated in December 2008. 
The  complete  MEDLINE  search  strategy  is  presented 
in Appendix 1. We also searched the SCOPUS abstract 
and citation database to pick up studies from relevant 
journals missed by the preceding search methods. To 
identify in-progress or planned studies, we searched 3 
trial registries: the UK National Research Register, the 
Australian  New  Zealand  Clinical  Trials  Registry  and 
the ClinicalTrials.gov database. We used the chemical 
abstracts database of the Scientific and Technical Infor-
mation Network and Google Scholar to identify relevant 
grey literature. We contacted the manufacturers of HES 
products (Bristol-Myers Squibb, Fresenius Kabi, B. Bru-
an, BioTime and Abbott Laboratories) to identify pub-
lished, unpublished and in-progress studies of HES for 
resuscitation. We searched the abstracts and conference 
proceedings of the European Society of Intensive Care 
Medicine,  the  International  Symposium  on  Intensive 
Care  Medicine,  the  Society  of  Critical  Care  Medicine, 
the  American  College  of  Chest  Physicians,  the  Amer-
ican  Thoracic  Society,  the  American  Society  of  Anes-
thesiologists,  the  Canadian  Anesthesiologists’  Society, 
the International Anaesthesia Research Society and the 
American Association for the Surgery of Trauma from 
2002 to 2007. We also searched the reference lists of all 
included studies and relevant reviews for suitable trials 
not identified by the electronic searches. No language re-
strictions were applied.  
We  included  randomized  controlled  trials  enrolling 
patients 18 years of age or older who were admitted to an 
ICU or emergency department and who had an indication 
for acute fluid resuscitation (hypovolemia, hypotension, 
inadequate indicators of preloading or filling pressures) 
and  that  compared  HES  with  crystalloids,  albumin, 
gelatins or dextran. The comparator fluids chosen are 
used for acute volume resuscitation in ICUs and emer-
gency departments throughout the world. We excluded Research                                                                                                                             Zarychanski et al
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crossover trials, trials in which blood was the compara-
tor fluid and trials examining HES fluids in elective sur-
gery or for acute normovolemic hemodilution. Although 
several different types of HES solutions are available for 
use, a uniform mechanism of injury was presumed to 
occur with all of these products. Thus, all HES solutions 
were considered in this review, but they were analyzed 
separately according to available data.
Our primary outcome was acute kidney injury, defined 
by the use of renal replacement therapy. Supplementary 
renal outcomes included the severity of kidney injury as 
defined by the RIFLE criteria (Risk of renal dysfunction, 
Injury to the kidney, Failure of kidney function, Loss of 
kidney function and End-stage kidney disease)24 and the 
measurement of urinary biomarkers indicative of kidney 
injury. Secondary clinical outcome measures were mor-
tality, duration of mechanical ventilation, duration of ICU 
stay, allergic reactions, bleeding and transfusion of packed 
red cell units. Mortality analyses were based on the long-
est time interval at which this outcome was assessed.
The  title,  abstract  and  keywords  of  each  record  in 
English were independently screened for relevance by 2 
reviewers (RZ and DM). Records excluded by both re-
viewers were eliminated at this stage. Full-text articles 
were obtained for all remaining records. Non-English re-
cords were translated by individuals who were fluent in 
the language of publication and who had specific train-
ing in medical sciences. Two reviewers (RZ and LM) then 
independently adjudicated each full-text article, apply-
ing the inclusion and exclusion criteria to select relevant 
trials. We calculated inter-rater agreement using Cohen’s 
kappa statistic.25 Non-English articles were adjudicated 
by a single reviewer (RZ) after translation. Discrepan-
cies were resolved by discussion and consensus with a 
third reviewer (DAF). 
Data extraction and quality assessment. Two review-
ers (RZ, AFT) independently abstracted data from the 
English-language trials using a standardized data ab-
straction form, which had been piloted to ensure com-
pleteness and feasibility. For each non-English trial, 1 
reviewer fluent in the language of publication abstracted 
the data. If essential data were ambiguous or missing, 
we contacted the first author or corresponding author by 
email.
Two  reviewers  assessed  the  methodologic  quality 
of each trial using the Jadad scale,26 which generates a 
score based on the description of randomization (0 to 
2 points), double-blinding (0 to 2 points) and partici-
pant withdrawals (1 point). Possible scores ranged from   
0 to 5; we considered a score of 3 or greater to repre-
sent high methodologic quality. We assessed allocation 
concealment using the method developed by Schulz and 
colleagues27 and scored it as “adequate,” “unclear” or “in-
adequate.” We used a double data-entry system to mini-
mize transcription errors. 
Data synthesis and analysis. Group sample means were 
compared using Welsh’s unpaired t test for unequal vari-
ances. Summary effect measures were calculated using 
Review Manager (version 4.2 for Windows, The Coch-
rane  Collaboration,  Oxford,  England).  We  performed 
analyses  according  to  the  intention-to-treat  principle 
using eligible randomized patients. We employed a ran-
dom-effects model using inverse variance weights for all 
summary measures of effect, expressing these as odds 
ratios (ORs) with 95% confidence intervals (CIs). An OR 
of more than 1 suggests a higher odds of the outcome 
among patients receiving HES than among patients in 
the control group.
We  assessed  for  evidence  of  statistical  heterogen-
eity  using  the  I2  statistic.  This  statistic  is  interpreted 
as the proportion of total variation across trials that is 
due to heterogeneity (minimum and maximum values 
0% and 100%). We investigated sources of heterogen-
eity by conducting subgroup analyses based on clinical 
and  methodologic  characteristics,  which  were  defined 
a priori: patient population, type of HES, type of fluid 
comparator, high- versus low-quality trials, presence or 
absence of allocation concealment and single-centre ver-
sus multicentre trials. We used funnel plots to visually 
examine the potential for publication bias.
Role of the funding source. There was no external fund-
ing source for this work.
Results
Of the 2381 reports identified, 2220 were excluded after 
initial  screening  (Fig.  1).  We  retrieved  full-text  arti-
cles for 161 studies published in 8 languages. Of these 
161  articles,  23  met  the  inclusion  criteria.  Substantial 
agreement between the 2 reviewers at level 1 and level 2 
screening is reflected in kappa values of 0.64 and 0.68, 
respectively.28 All discrepancies were resolved by discus-
sion and consensus. During data extraction, we found 
that 2 publications were separate analyses of the same 
trial  population;29,30  we  included  only  the  article  that 
was most informative for the purposes of this review.30 
From trial registries, we identified 3 randomized trials 
in progress, but we did not include these in our analyses. Research                                                                                                                            Zarychanski et al
The 22 trials accounted for a total of 1865 patients, with 
a median of 48 patients enrolled per trial (range 12–537). 
Twenty-one trials were published in peer-reviewed jour-
nals, and 1 was published in abstract form.31 Twenty trials 
were  reported  in  English-language  journals,7,8,18,19,30–45 
1  was  in  French46  and  1  was  in  German.47  Five  trials 
were conducted in North America,19,30,40,42,44 16 in Eur-
ope7,8,18,31–39,41,43,46,47  and  1  in  South  America.45  Four 
trials  received  grant  funding  from  manufacturers  of 
HES,18,19,42,44 2 received government support,7,41 and 16 
trials reported no funding source.8,30–40,43,45–47 
Eight trials enrolled patients with sepsis, severe sepsis 
or septic shock but no trauma,7,18,19,38,40,41,43,44 6 enrolled 
patients  with  trauma,31,32,37,42,45,46  5  enrolled  patients 
with trauma or sepsis,33–36,39 and 1 enrolled patients with 
“hypovolemic shock”;30 1 study did not report the type of 
critically ill patients who formed the study population.47 
One trial involved organ donors with brain death, who 
were randomly assigned to receive either HES or gelat-
in;8 in that study, the final unit of analysis was number of 
transplanted kidneys.  
The  trials  compared  HES  with  20%  albumin,33–39,43 
5%  albumin,30,40,44  gelatin,7,8,31,32,41,46,47  dextran,31  or  a 
crystalloid solution (Table 1).18,19,30,42,45 Two trials includ-
ed pentoxifylline as a third-arm comparator, but these 
arms  were  not  included  in  this  systematic  review  be-
cause pentoxifylline is not used for resuscitation.37,38 Six 
different HES fluids, varying by molecular weight and 
molar substitution, were represented.  
All  of  the  trials  enrolled  patients  requiring  urgent 
fluid resuscitation; however, the eligibility criteria var-
ied widely and were not explicitly stated in 2 of the full 
publications32,47 or the single abstract.31 Many trials used 
either  low  systolic  blood  pressure  or  low  mean  arter-
ial blood pressure as justification for fluid administra-
tion.7,18,19,30,40,42,44–46 Three trials incorporated increased 
arterial lactate and cardiac index less than 2.2 L/min as 
criteria for fluid loading.30,40,44 In 8 trials, central ven-
ous pressure or pulmonary capillary wedge pressure less 
than 10–15 mm Hg served as the single trigger for vol-
ume loading.33–39,43 One trial incorporated clinical signs 
of hypoperfusion.46 Two trials used echocardiographic 
indicators as surrogates for hypovolemia.8,41 
The amount and type of fluid received before random-
ization was reported in 4 trials.18,19,36,43 The duration of the 
study protocol varied from less than 2 hours to 21 days. 
Twelve protocols involved administration of HES with-
in the first 24 hours after presentation.8,19,30–32,40–42,44–47 
The total amount of study fluid administered differed 
considerably among the trials; in particular, the mean 
volume  of  HES  given  varied  from  364  mL  (standard 
deviation [SD] 64)45 to 5350 mL (SD 650).38
Relevant  cointerventions  were  reported  for  several 
studies. All patients in the trials conducted by Boldt and 
colleagues33–39  received  continuous  infusions  of  dopa-
mine at 3 µg/kg per minute. In 1 trial, gelatin was admin-
istered to the HES group after they had received 2000 
mL of the study colloid.46 In another trial, the protocol 
specified  that  the  components  of  early  goal-directed 
therapy would include transfusion of red blood cells and 
infusion of inodilators, in addition to the study fluid.19 In 
all studies, vasopressors and inotropes were used when 
necessary, generally after initial volume resuscitation.
Four trials listed renal sequelae as primary or second-
ary outcomes.7,8,18,19 Four trials reported the requirement 
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Trials included  n = 22
Records excluded by level 1 screening  n = 2220
•  Duplicate records  n = 801
•  Irrelevant  n = 906
•  Diﬀerent target population  n = 407
•  Reviews  n = 59
•  Studies other than parallel RCT  n = 28
•  Unsuitable comparator  n = 12
•  Letters  n = 7
Figure 1: Study flow diagram 
Records excluded on level 2 screening   n = 139
•  Elective surgery, irrelevant population   n = 73
•  Studies other than parallel RCT  n = 29
•  Review, correspondence  n = 17
•  Not resuscitation  n = 6
•  Irrelevant  n = 6 
•  Duplicate publications  n = 4
•  Abstracts of published manuscript  n = 3
•  Abstract only (insuﬃcient data)  n = 1
Records identified from bibliographic databases 
and manual methods  n = 2381   
•  Electronic search (MEDLINE, EMBASE, Cochrane)  n = 2357
•  SCOPUS abstract and citation database  n = 19
•  Conference abstracts, hand-searching  n = 5
  
 
Records retrieved for full-text review  n = 161Open Medicine 2009;3(4):e196–209
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 for  renal  replacement  therapy,7,8,18,19  and  5  trials  re-
ported a definition for acute renal failure based on cre-
atinine  concentration.7,8,18,32,39  Patients  with  evidence 
of renal impairment or renal failure, defined by serum 
creatinine or the need for hemodialysis, were excluded 
from 9 trials.7,18,19,32–36,43 Baseline renal function (serum 
creatinine) was reported in 5 trials.7,8,18,19,39 Comorbidities 
and risk factors for renal injury were detailed in 2 trials.7,18
Most of the trials included in this review were small, 
involved a single centre and had low methodologic qual-
ity (Table 2). We could not assess most aspects of the 
methodologic quality of the study that was available in 
abstract form only.31 Four trials were of high methodo-
logic quality (Jadad score of at least 3).7,8,18,19 Adequate 
allocation concealment was reported in 5 trials.7,18,19,45,46 
Nine of the 21 evaluable trials reported blinding,8,19,33–39 
but only 1 described the blinding method.19 Losses to 
follow-up were reported in 5 trials.7,8,18,19,32 Analysis ac-
cording to the intention-to-treat principle was reported 
in 4 trials.7,8,18,19 The method of analysis was unclear in 16 
trials because information about losses to follow-up was 
not reported.30,33–47  
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Table 2: Methodologic quality and potential risks of bias in the included randomized controlled trials  
Jadad score* 
Study  RCT type  Sponsor  Total  Randomization  Blinding 
Attrition 
information 
Allocation 
concealment  ITT analysis 
Brunkhorst
18  Multicentre  Unrestricted industry 
grant plus public funds 
3  2  0  1  Adequate  Yes 
McIntyre
19  Multicentre  Bristol Myers Squibb 
(unrestricted grant) 
5  2  2  1  Adequate  Yes 
Palumbo
43  Single centre  NR  1  1  0  0  Unclear  Unclear 
Molnar
41  Single centre  Ministry of Education, 
Hungary 
1  1  0  0  Unclear  Unclear 
Schortgen
7  Multicentre  Assistance Publique-
Hôpitaux de Paris 
3  2  0  1  Adequate  Yes 
Carli
46  Multicentre  NR  1  1  0  0  Adequate  Unclear 
Allison
32  Single centre  NR  1  0  0  1  Inadequate  No 
Boldt
39  Single centre  NR  2  1  1  0  Unclear  Unclear 
Younes
45  Single centre  NR  1  1  0  0  Adequate  Unclear 
Jovanovic
31 
(abstract) 
NE  NR  NE  1  NE  NE  NE  NE 
Cittanova
8  Single centre  NR  3  1  1  1  Unclear  Yes 
Boldt
34  Single centre  NR  2  1  1  0  Unclear  Unclear 
Boldt
36  Single centre  NR  2  1  1  0  Unclear  Unclear 
Boldt
37  Single centre  NR  2  1  1  0  Unclear  Unclear 
Boldt
35  Single centre  NR  2  1  1  0  Unclear  Unclear 
Boldt
38  Single centre  NR  2  1  1  0  Unclear  Unclear 
Boldt
33  Single centre  NR  2  1  1  0  Unclear  Unclear 
Nagy
42  Single centre  American Critical Care  1  1  0  0  Unclear  Unclear 
Rackow
44  Single centre  Dupont  1  1  0  0  Unclear  Unclear 
Falk
40  Single centre  NR  1  1  0  0  Unclear  Unclear 
Hopf
47  Single centre  NR  1  1  0  0  Unclear  Unclear 
Haupt
30  Single centre  NR  1  1  0  0  Unclear  Unclear 
*The Jadad scale allows assignment of a methodologic quality score based on the reported methods and description of randomization (0–2 points), blinding (0–2 
points) and the reporting of participant withdrawals (0–1 point). Possible scores range from 0 to 5, with a score of 5 indicating high methodologic quality. 
RCT = randomized controlled trial, ITT = intention to treat, NR = not reported, NE = not evaluable. Primary outcome: acute kidney injury. The pooled OR 
for renal replacement therapy associated with HES fluid 
for the 4 trials that reported this outcome was 1.90 (95% 
CI 1.22–2.96, I2 9.5%, n = 749)7,8,18,19 (Fig. 2). The sum-
mary statistic was heavily influenced by the findings of 
a single large randomized controlled trial that accounted 
for 70% of the pooled statistical weight.18 Three of these 
4  trials  included  patients  with  severe  sepsis  or  septic 
shock,7,18,19 for which the pooled OR of renal replacement 
therapy was 1.82 (95% CI 1.27–2.61, I2 0%, n = 702). HES 
use was also associated with greater odds of renal re-
placement therapy in the single trial of kidney transplant 
recipients (OR 9.5, 95% CI 1.09–82.72, n = 47).8 Further 
sensitivity analyses were limited by the low number of 
trials that reported renal outcomes. In 1 study reporting 
renal replacement therapy as an outcome, the baseline 
measures of renal function differed between the HES 
and control groups (see below).7 
Indices reflecting changes in serum creatinine were 
reported in 5 trials but were not suitable for pooling be-
cause of variable definitions of acute kidney injury and 
variable timing of laboratory measurements.7,8,18,32,39 In 
the trial involving kidney transplant donors and recipi-
ents, serum creatinine values were higher in the first 10 
days after transplantation among patients who received 
kidneys from donors resuscitated with HES than among 
patients who received kidneys from donors resuscitated 
with gelatin (p < 0.01).8 In another trial of resuscitation 
in septic shock, the median peak serum creatinine was 
higher among those who received HES 200/0.60 (mo-
lecular  weight/molar  substitution)  than  among  those 
who received gelatin (2.5 [interquartile range 1.5–3.8] 
mg/dL v. 1.9 [1.2–3.1] mg/dL, p = 0.04).7 However, in 
that trial, the baseline serum creatinine concentrations 
were significantly higher among patients randomly as-
signed to receive HES. Two trials that included patients 
with trauma and sepsis or trauma alone reported similar 
mean serum creatinine values in the HES and control 
groups; these analyses were based on patients remain-
ing in the ICU at day 5.32,39 None of the trials evaluated 
acute kidney injury according to the RIFLE categories or 
characterized changes in urinary biomarkers.
For  the  2  trials  that  enrolled  patients  with  severe 
sepsis and septic shock, the pooled OR for acute kidney 
injury, defined as a doubling of serum creatinine or the 
requirement for renal replacement therapy, was 1.91 (95% 
CI 1.36–2.68, I2 0%, n = 666) among patients receiving 
HES.7,18 In 1 trial, which reported acute kidney injury as 
creatinine above 221 µmol/L or urine output less than 20 
mL/h, there were no differences between the 2 groups.39
Open Medicine 2009;3(4):e196–209
Research                                                                                                                             Zarychanski et al
 
Favours 
hydroxyethyl 
starch 
Favours 
control 
Odds ratio 
(95% CI) 
No. of  
events 
No. of  
participants 
1.95 (1.30–2.91) 
McIntyre
19  3.00 (0.28–31.63) 
Schortgen
7  1.20 (0.49–2.93) 
Cittanova
8  9.50 (1.09–82.72) 
1.90 (1.22–2.96)  Overall 
Patient population 
Type of comparator 
Subgroup analyses 
Severe sepsis/septic shock   1.82 (1.27–2.61) 
Organ 
transplantation 
9.50 (1.09–82.72) 
Gelatin  2.64 (0.37–18.96) 
Crystalloid  1.98 (1.33–2.94)  
HES 
81/261 
3/21 
13/65 
9/27 
106/374 
97/347 
9/27 
22/92 
84/282 
Control 
51/272 
1/19 
11/64 
1/20 
64/375 
53/355 
1/20 
12/84 
52/291 
Studies 
n 
3 
1 
4 
2 
2 
Study 
Brunkhorst
18 
All studies 
Odds ratio (95% CI) 
0.01  0.1  1  10  100 
Figure 2: Renal replacement therapy associated with hydroxyethyl starch (HES) Secondary outcomes: mortality, duration of mechan-
ical ventilation and ICU stay. Mortality was reported for 
17 of the 22 trials (Fig. 3). The pooled OR for death asso-
ciated with HES was 1.07 (95% CI 0.85–1.34, I2 0%, n = 
1657). For the 6 trials that enrolled patients with severe 
sepsis or septic shock, the pooled OR for death associ-
ated with HES was 1.23 (95% CI 0.92–1.64, I2 0%, n = 
782);7,18,19,38,41,44 in trials of patients with trauma, the OR 
for death was 1.52 (95% CI 0.48–4.75, I2 25%, n = 294); 
and in trials that included patients with either sepsis or 
trauma, the OR for death was 0.82 (95% CI 0.55–1.21, I2 
0%, n = 532) (Fig. 4). No significant differences in ORs for 
death were evident with different durations of the study 
protocols or with use of early goal-directed therapy (data 
not shown). Similarly, no significant differences in the 
OR for death occurred with the various fluid comparator 
groups or when specific molecular weights of HES were 
analyzed (Fig. 4). 
In the 3 trials of higher methodologic quality (Jadad 
score 3–5) that provided mortality data, the pooled OR 
for death was 1.27 (95% CI 0.93–1.72, I2 0%, n = 704).7,18,19 
In  the  5  trials  with  adequate  allocation  concealment, 
the summary OR for death associated with the use of 
HES was 1.28 (95% CI 0.96–1.72, I2 0%, n = 891) (Fig. 
4).7,18,19,45,46  In the 4 multicentre trials, HES administra-
tion was associated with an OR for death of 1.31 (95% CI 
0.97–1.76, I2 0%, n = 868).7,18,19,46 
The duration of mechanical ventilation39,42 and venti-
lator-free days18 was similar for the 3 trials reporting 
these outcomes. The mean41 or median7,18,19 duration of 
the ICU stay was comparable between the HES and con-
trol groups in 4 of the trials of septic shock. In 1 trial 
of 59 patients with acute traumatic injuries, mean (SD) 
ICU length of stay was shorter (8.8 [3.3] days v. 11.1 [3.4] 
days, p = 0.01) among patients who received HES.32  
Safety  outcomes.  Three  of  the  22  included  trials  re-
ported  information  about  allergic  reactions  or    an-
aphylaxis  secondary  to  administration  of  HES.8,44,46 
No allergic reactions were reported in these 3 studies, 
which accounted for 11% (n = 211) of all patients enrolled. 
One study (n = 23) explicitly reported no complications 
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Figure 3: Overall mortality of all included studies related to the infusion of HES,45 and 1 study reported no 
differences in a composite measure of serious adverse 
events, which included allergic reactions and bleeding.18 
Insufficient  and  heterogeneous  reporting  of  coagu-
lopathy,  bleeding  and  red  cell  transfusions  precluded 
pooled analyses and summary statements for these ad-
verse events.  
Publication bias. We minimized the potential for pub-
lication bias by conducting an extensive search of the 
literature, including grey literature sources, consulting 
content experts and avoiding language restrictions. Fun-
nel plot analysis was not possible for renal outcomes be-
cause only 4 trials reported such outcomes. No pattern 
consistent with publication bias was evident on the fun-
nel plots generated for the outcome of mortality (Fig. 5).  
Discussion
In this systematic review, we found that the use of HES 
for  acute  volume  resuscitation  of  critically  ill  patients 
was associated with 90% greater odds of renal replace-
ment therapy for the 4 trials reporting this outcome (OR 
1.90, 95% CI 1.22–2.96). For the 3 trials that enrolled 
patients with severe sepsis or septic shock, the odds of 
receiving  renal  replacement  therapy  was  82%  greater 
(OR  1.82,  95%  CI  1.27–2.61).  No  difference  in  overall 
mortality was found; however, among studies enrolling 
patients with severe sepsis and septic shock, and in trials 
that involved more than one centre, that had high meth-
odologic  quality  or  that  reported  adequate  allocation 
concealment, there was a trend toward greater odds of 
death in association with HES. Serious adverse events, 
including bleeding or coagulopathy, were poorly charac-
terized and inadequately reported.
HES  solutions  are  effective  volume  expanders  but 
are deposited widely in the tissues, including the skin, 
liver, muscle, spleen, endothelial cells and kidneys.48,49 
Just as persistent and significant pruritus is now rec-
ognized as a deleterious consequence of starch admin-
istration,49  so  too  are  the  potential  consequences  for 
the kidney.48,50 Case reports, observational studies and 
randomized controlled trials involving various patient 
populations  exposed  to  different  HES  fluids  have  in-
consistently reported the occurrence of adverse kidney 
outcomes.4,13,14,16,17,48 Although each HES compound has 
unique pharmacokinetic properties that depend on the 
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Figure 4: Mortality according to patient population, type of HES, type of comparator fluid  
and methodologic quality mean molecular weight, the degree of substitution and 
the C2:C6 ratio,51 it is unclear whether these differences 
affect clinically important outcomes.   
This  systematic  review  had  several  limitations.  Al-
though patients assigned to receive HES were more like-
ly to receive renal replacement therapy across all trials 
that  reported  this  outcome,  the  pooled  analyses  were 
substantially influenced by 1 large trial of patients with 
severe sepsis and septic shock.18 Notably, this trial was 
not blinded, there were violations of the fluid protocols 
in both study arms (for 26% of the patients in the HES 
arm and 27% of those in the crystalloid arm), and the 
dose limit for HES (20 mL/kg per day) was exceeded in 
38% of patients on at least day 1 of the study protocol.
In addition, the heterogeneous clinical and methodo-
logic characteristics of the trials included in this review 
presented challenges for making inferences. Differences 
in the primary and secondary outcome rates might have 
been influenced by the patient population and duration 
of follow-up in each study. Similarly, event rates might 
have differed according to the type of HES and the com-
parator fluids, as well as the dosing, duration of exposure 
and reasons for administering fluid. Few trials reported 
important baseline characteristics, such as illness sever-
ity, or potential risk factors or exposures for acute kid-
ney injury, which would be essential for ensuring that 
study groups were similar at randomization. Few trials 
reported relevant cointerventions or details of key renal 
outcomes such as the duration of renal replacement ther-
apy, renal recovery, the progression to chronic kidney 
disease or dependence on dialysis. 
Nevertheless,  the  development  of 
acute kidney injury in critically ill 
patients,  independent  of  receiv-
ing renal replacement therapy, has 
been associated with higher mor-
tality.12  Whether  or  not  patients 
with severe sepsis or septic shock 
should receive colloids, especially 
HES,  for  initial  (e.g.,  “early  goal-
directed”) volume resuscitation re-
quires further investigation.
An  HES  fluid  with  lower  mo-
lecular weight and less substitution 
is currently available and is being 
marketed  as  having  an  excellent 
safety  profile;52  however,  there  is 
as yet no published evidence from large, definitive ran-
domized controlled trials in critically ill patients to con-
firm the efficacy or safety of this solution. Moreover, all 
manufacturers of starch solutions list kidney dysfunc-
tion and/or oliguria as contraindications.
The clinical use of colloidal starch solutions, includ-
ing HES, has increased despite their higher cost relative 
to crystalloid solutions (M. Baker, Concordia Hospital, 
Winnipeg,  Manitoba;  M.  Haun,  Canadian  Blood  Ser-
vices,  Ottawa,  Ontario;  personal  communications  by 
email, 2008) and a lack of evidence of their clinical su-
periority.2,20,21,48  HES  products  now  appear  in  several 
resuscitation guidelines, including the those of the US 
Hospital Consortium.53 However, our systematic review 
has documented that HES administered to critically ill 
patients  appears  to  be  associated  with  greater  use  of 
renal replacement therapy. This finding was consistent 
across the 3 studies of patients with severe sepsis and 
septic shock that reported this adverse outcome. It is 
unclear whether this adverse effect applies to all HES 
fluids  and  all  critically  ill  patients.  Methodologically 
rigorous,  adequately  powered  randomized  controlled 
trials with the newer, lower-molecular-weight and less 
substituted  starch  solutions  are  necessary  to  define 
the clinical benefits and potential risks associated with 
their use in critically ill patients. Until the results of 
such studies become available, we do not recommend 
the routine use of starches for acute volume resuscita-
tion in critically ill patients, particularly patients with 
severe sepsis or septic shock.
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Appendix 1: MEDLINE search strategy
Database: Ovid MEDLINE(R) <1950 to August Week 2 2007>
Search strategy:
  1     hetastarch/ (1694)
  2     hetastarch$.tw. (324)
  3     (hydroxyethyl starch$ or hydroxyethylstarch$).tw. (1747)
  4     pentastarch$.tw. (100)
  5     (haes-steril or Hextend or Elohes or Expafusin or Voluven 
         or hemohes or hespan or pentafraction or pentaspan
         or plasmasteril).tw. (214)
  6     hes.tw. (2087)
  7     or/1-6 (3725)
  8     randomized controlled trial.pt. (240431)
  9     controlled clinical trial.pt. (75750)
10     randomized controlled trials.sh. (50403)
11     random allocation.sh. (58745)
12     double blind method.sh. (92784)
13     single-blind method.sh. (11237)
14     clinical trial.pt. (439656)
15     exp clinical trials/ (195189)
16     (clin$ adj25 trial$).ti,ab. (134236)
17     ((singl$ or doubl$ or trebl$ or tripl$) adj25 
          (blind$ or mask$)).tw. (92205)
18     placebo$.sh. (27848)
19     placebo$.ti,ab. (104329)
20     random$.ti,ab. (382044)
21     research design.sh. (48798)
22     comparative study.pt. (1358262)
23     exp evaluation studies/ (610724)
24     follow up studies.sh. (344218)
25     prospective studies.sh. (226595)
26     (control$ or prospectiv$ or volunteer$).ti,ab. (1825986)
27     or/8-26 (3854705)
28     animals/ not humans/ (3168650)
29     27 not 28 (3008945)
30     7 and 29 (1177)
Updated December Week 2 2008